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INTRODUCTION
Non-variceal  upper  gastrointestinal  bleeding 
(UGIB)  remains  a  common  and  challenging 
emergency  for  gastroenterologists  and  general 
physicians. The annual incidence is 50 to 150 per 
100,000 of the population, and, even though there 
have been significant improvements in endoscopic 
and  supportive  therapies,  the  overall  mortality 
stubbornly  remains  around  10%,  and  may  even 
reach  35%  in  hospitalised  patients  with  serious 
co-morbidity. Patients aged over 80 years of age 
now  account  for  around  25%  of  all  UGIB  and 
33% of UGIB occurring in hospitalized patients 
and therefore tend to account for much of the poor 
outcome of this condition.1
The causes of non-variceal UGIB are shown in 
(Table I), although the commonly quoted figure of 
50% for peptic ulcer bleeding may be overestimated. 
In a recent large CORI (Clinical Outcome Research 
Initiative)  study  of  UGIB,  peptic  ulcer  was  the 
probable cause of UGIB in only 20% of cases.2 
The incidence of peptic ulcer disease is expected 
to  continue  to  decline  with  more  widespread 
helicobacter pylori eradication and proton pump 
inhibitor (PPI) usage.
RISK ASSESSMENT AND INITIAL MANAGEMENT
Several  clinical  scoring  systems  e.g.  Rockall 
score,  the  Baylor  bleeding  score,  the  Cedars-
Sinai  Medical  Centre  Predictive  Index  and  the 
Blatchford score, have been developed to direct 
appropriate patient management and enable cost 
effective use of resources. These systems weigh a 
combination of clinical, laboratory and endoscopic 
variables  to  produce  a  score  that  predicts  the 
risk  of  mortality,  recurrent  haemorrhage,  need 
for  clinical  intervention  or  suitability  for  early 
discharge. Factors commonly associated with poor 
outcome from UGIB may be related to the patient’s 
presentation and co-morbidities, or to the behaviour 
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of the ulcer (Table II). Risk stratification using non-
endoscopic parameters has the advantage that it can 
be performed readily on initial presentation in the 
emergency department, and appropriate initial risk 
assessment is still possible, even if early endoscopy, 
which requires skilled staff and resources, is not 
always available.
Inclusion  of  endoscopic  stigmata  of  recent 
haemorrhage (SRH) that relate to increased risk of 
re-bleeding and death into scoring systems increases 
the sensitivity for predicting patients at high or low 
risk  compared  to  non-endoscopic  assessments.3-5 
High risk lesions such as actively bleeding ulcers, 
non-bleeding visible vessels (NBVV) and adherent 
clots  (Table  III)  require  effective  aggressive 
intervention  to  reduce  re-bleeding  which  is 
associated with a 5-16 fold increase in mortality.6, 7 
The re-bleeding rate of ulcers with a clean base 
or  red  or  blue  spots  are  low  and  endoscopic 
intervention  is  usually  not  recommended.8-10  In 
fact, early endoscopy-based triage may permit safe 
and early discharge of “low risk” patients with no 
increased rate of re-bleeding or mortality.11
Endoscopic  SRH,  particularly  NBVV  and  flat 
pigmented spots, can be difficult to differentiate.12 
Doppler assessment is unlikely to be widely available 
for some time because of technical and resource ©  The Ulster Medical Society, 2006.
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Table I
Causes of non-variceal UGIB
Table II
Predictors of adverse outcome from UGIB
Patient:  Shock
  Melaena
  Significant fresh blood in vomit, gastric aspirate or rectum
  Sepsis
  Anaemia at presentation
  Cardiac/ liver/ renal disease
Ulcer:  Large ulcer size
  Persistent bleeding despite endoscopic therapy
  Recurrent bleeding
  Forrest class  Type of lesion  Risk of rebleed if untreated [%]
  Ia  Arterial spurting  100
  Ib  Arterial oozing  17-100
  IIa  Visible vessel  8-81
  IIb  Sentinel clot  14-36
  IIc  Haematin covered flat spot  0-13
  III  No stigmata  0-10
  Diagnosis  Incidence [%]
  Peptic ulcer  20 – 50
  Mallory-Weiss tear  15 – 20
  Erosive gastritis/ duodenitis  10 – 15
  Oesophagitis/ oesophageal ulcer  5 – 10
  Malignancy  1 – 2
  Angiodysplasia/ vascular malformations  5
  Other  5
Table III
Forrest classification of peptic ulcers in UGIB©  The Ulster Medical Society, 2006.
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limitations, but may be effective at differentiating 
between patent vasculature and pigmented spots.13 
In  this  study  there  was  agreement  between  the 
endoscopic  Forrest  classification  and  Doppler 
assessment in only 58% of cases, suggesting that 
Doppler was more sensitive at detecting high-risk 
lesions. Re-bleeding, requirement for surgery and 
mortality rate were all significantly lower in the 
Doppler-assessed endoscopically treated group. 
Resuscitation  and  management  of  medical 
co-morbidities,  often  in  intensive  care  or  high 
dependency,  remains  the  mainstay  of  the  initial 
management of patients prior to endoscopy. The 
presence  of  blood-stained  nasogastric  aspirate 
can be used to predict the presence of high risk 
lesions  and  nasogastric  tube  insertion  should 
be  considered  for  some  patients.14  The  role  of 
endotracheal intubation remains controversial; the 
benefits are easier endoscopy and reduced risk of 
massive aspiration in patient with a reduced level 
of consciousness, but evidence of a reduction in 
acquired pneumonia or cardiopulmonary events is 
lacking.15, 16
ENDOSCOPIC MANAGEMENT
Endoscopic  intervention  reduces  the  rate  of 
re-bleeding,  need  for  surgical  intervention  and 
mortality in high risk patients with UGIB.17 The 
optimum timing of endoscopy remains a balance 
between clinical need and resources, but endoscopy 
performed within 24 hours of hospital admission 
has been shown to reduce the length of hospital 
stay and may reduce the likelihood of re-bleeding 
or surgical intervention in the highest risk patients.18 
Not infrequently, excessive blood in the upper GI 
tract may preclude an accurate endoscopic diagnosis 
in  a  small  number  of  patients.  These  patients 
have a significantly higher rate of complications, 
rebleeding, need for surgery and mortality.19 Bolus 
administration of intravenous erythromycin prior 
to endoscopy has been shown to clear the stomach 
of  blood,  increase  the  likelihood  of  successful 
haemostasis and reduce the need for subsequent 
interventions.20, 21
Most haemostatic techniques are equally effective 
when used alone, although doubt has been cast on 
the value of “stand alone” therapy with adrenaline 
injection. Recent focus has been directed towards 
combination  therapies  and  mechanical  means 
of  homeostasis.  Injection  of  dilute  (1:10  000) 
adrenaline  in  1ml  aliquots  around  the  bleeding 
points has traditionally been the main method of 
haemostasis  in  Europe,  whereas  application  of 
heat is the preferred strategy in the United States. 
Adrenaline injection results in haemostasis in up 
to100%  of  patients  with  bleeding  peptic  ulcers, 
probably by a combination of vascular tamponade 
and vasoconstriction, with a concomitant reduction 
in re-bleeding rates from 40 to 15%.22, 23 The dose 
of adrenaline required to achieve haemostasis is 
variable but larger volumes (13-20ml vs. 5-10ml) 
in high risk patients (Forrest type I or IIa lesions) 
results  in  less  re-bleeding  (15.4%  vs.  30.8%).24 
Although injection with adrenaline is successful in 
achieving initial haemostasis, 15-36% of patients 
rebleed, a figure that is unacceptably high.25, 26
Sclerosants  such  as  ethanol,  polidocanol  and 
ethanolamine are equally effective as adrenaline but 
carry more risk.25, 27-29 In one study, ethanol injection 
alone was shown to have a re-bleeding rate as low 
as 4%;30 however, most other published studies have 
achieved similar haemostasis to adrenaline alone.   
Combination therapy with adrenaline and ethanol 
may improve haemostasis and shorten hospital stay 
for patients with spurting haemorrhage.28
The evidence for thrombin injection is mixed with 
differing reports of effect on clinical outcomes.31- 33 
Repeated daily injection of fibrin glue following 
treatment with dilute adrenaline in patients with 
active  bleeding  or  NBVV  until  the  ulcer  base 
is clean or covered is expensive but reduces re-
bleeding although not mortality rates.34
N-butyl-2-cyanoacrylate  (Histoacryl)  injection 
has  been  shown  to  be  effective  for  control  of 
variceal  bleeding,35  but  its  role  in  non-variceal 
UGIB  remains  uncertain.  In  a  small  study  of 
32  patients  with  bleeding  ulcers,  Histoacryl 
injection  was  no  more  effective  than  injection 
with dilute adrenaline.25 More recently, Lee et al 
demonstrated significantly lower re-bleeding rate 
for patients with Forrest type Ia lesions treated with 
Histoacryl compared to injection with hypertonic 
saline-adrenaline injection.36 However, there was 
no overall benefit in the use of Histoacryl with 
regards to haemostasis rates, emergency surgery 
or mortality. Arterial embolisation is a recognized 
complication of this treatment and means that this 
therapy is recommended as a measure of last resort 
because of potentially fatal adverse effects.
In  contrast  to  injection  techniques,  thermal 
haemostasis  is  achieved  by  compression  of 
the  artery  during  heating  (coaption)  and/or  the ©  The Ulster Medical Society, 2006.
Non-variceal upper gastrointestinal bleeding 35
www.ums.ac.uk
effect  of  heat  on  tissue.  The  only  non-contact 
thermal techniques currently available are Argon 
Plasma Coagulation (APC) and laser (Nd:YAG). 
APC  involves  conduction  of  a  high  frequency 
electrical current through a beam of ionized argon 
gas,  resulting  in  superficial  tissue  damage  and 
coagulation.  A  prospective  observational  study 
of APC in 254 patients with non-variceal UGIB 
revealed  initial  haemostasis  rates  of  75.9%  and 
re-bleeding  rates  of  5.7%.37  The  addition  of  a 
second haemostasis technique increased successful 
haemostasis  to  99.6%.  The  only  comparative 
randomised  trial  involving  APC  alone  with 
heater  probe  was  underpowered,  although  rates 
of  haemostasis,  rebleeding,  emergency  surgery 
and  30  day  mortality  were  similar  for  the  two 
techniques.38 A larger prospective randomised study 
of dual therapies for bleeding peptic ulcers showed 
no significant difference in primary haemostasis, 
procedure duration, re-bleeding, requirement for 
surgery, 30-day mortality or ulcer healing at 8 weeks 
between treatment with adrenaline and heater probe 
versus adrenaline and APC.39 ND:YAG laser therapy 
has been shown to be as effective than injection 
with adrenaline-polidocanol,40 but, due to technical 
constraints of the technique, laser therapy is not 
routinely used in the management of non-variceal 
UGIB.
In  contrast  to  APC  and  laser,  Bipolar 
Electrocoagulation  (BPE)  and  Heater  Probe 
Thermocoagulation (HPT) use thermal contact to 
achieve haemostasis by compression of the vessel 
and  coaption.  BPE  devices  sometimes  include 
an injector/irrigator component (e.g. Gold probe, 
Boston Scientific, MA), which allows injection of 
adrenaline or irrigation of the lesion. BPE reduces 
the re-bleeding rate when compared with normal 
saline  injection  in  high  risk  bleeding  ulcers,41 
and compared to medical therapy when used in 
combination with adrenaline in Forrest IIb ulcers.42 
Combination therapy with HPT and adrenaline in 
the  treatment  of  actively  bleeding  peptic  ulcers 
resulted  in  haemostasis  in  up  to  98.6%,  with 
re-bleeding in 8.2%,43 although added benefit is 
confined to high risk lesions.26 When used alone, 
HPT was not superior to combination treatment 
with adrenaline and polidocanol in patients with 
Forrest  type  I,  IIa  and  IIb  ulcers.44 There  is  no 
incremental benefit of adding thrombin to HPT in 
patients with bleeding peptic ulcers with regards 
to haemostasis, re-bleeding rates, requirement for 
surgery, adverse events or mortality.45
Mechanical haemostasis with endoloops or clips, 
e.g.  the  Hemoclip  (Teleflex  Medical,  PA),  has 
an increasing role in the control of non-variceal 
UGIB.  Endoclips  are  deployed  on  a  visible 
vessel to achieve vascular compression and can 
achieve  homeostasis  in  up  to  100%  of  cases.46 
Comparative  studies  suggest  lower  re-bleeding 
rates than adrenaline injection,47 ethanol  48 or saline/
adrenaline  injection.49  The  additional  benefit  of 
adrenaline with a mechanical method is unclear,50 
although  one  randomised  comparative  study  of 
combination  epinephrine-polidocanol  injection 
and Hemoclip versus Hemoclip alone for bleeding 
peptic  ulcers  showed  clipping  to  be  inferior  to 
combination  therapy.51  Two  small  studies  have 
evaluated Hemoclips for control of bleeding due to 
Dieulafoy’s lesion, demonstrating a trend towards 
reduction  in  the  need  for  repeat  procedures.52, 53 
Hemoclips can be technically difficult to apply if the 
ulcer is relatively inaccessible, for instance high on 
the gastric lesser curve or on the posterior duodenal 
wall. In fact, application of a clip with successful 
haemostasis in either of these locations has been as 
low as 30% in published series. Rotatable, versatile 
endoclips that can deploy multiple and/or stronger 
clips are needed.
Endoscopic  band  ligation  (EBL)  is  currently 
technically easier to use than endoclips and has 
been shown to be safe and effective for control of 
small lesions in a small series of acute peptic ulcer 
bleeding  54 and with bleeding due to Dieulafoy’s 
lesions.55
ADHERENT CLOTS
Subgroup analysis of patients with adherent clots 
in early endoscopic studies demonstrated little or 
no benefit of endoscopic therapy for ulcers with 
adherent clots.56-59 However, a subsequent meta-
analysis showed significant benefit in the group 
of  patients  with  active  bleeding  or  NBVV .17 To 
further address this issue, a recent controlled trial 
in patients with severe UGIB and adherent clot 
randomised 32 patients to “medical” or combination 
endoscopic  therapy  following  clot  removal.42 
Endoscopic  therapy  consisted  of  adrenaline 
injection, shaving of the clot with cold guillotine 
and BPE of the underlying ulcer SRH. Combination 
endoscopic therapy was safe and associated with 
less early re-bleeding compared to medical therapy, 
although the small sample size, unexpectedly low 
re-bleed rates in the combination therapy group 
[0%]  and  unequal  distribution  of  confounding ©  The Ulster Medical Society, 2006.
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factors in the two groups means that caution needs 
to be taken when extrapolating the results. Also, 
even in clinical trials there tends to be significant 
intra-observer variation in the labelling of SRH 
and the degree clot “adherence” depending on the 
method of removal employed.60, 61 For instance, in 
one study five minutes of irrigation via a bipolar 
probe was found to remove clot in 43% of patients, 
whereas irrigation with a syringe via the endoscope 
channel only removed 9% of clots.62 Placement of 
a transparent irrigating hood over the endoscope 
tip  that  allows  forceful  irrigation  yet  maintains 
a reasonable endoscopic view may prove useful 
for clot removal and may reduce total procedure 
time.63, 64 Although the optimum technique for clot 
removal is unclear, clot removal should be attempted 
as high risk SRH may be exposed in the underlying 
ulcer in around a further 30% of patients. Current 
practice among experienced endoscopists involves 
targeted  irrigation  and  possibly  snare  guillotine 
of an adherent clot followed by treatment of the 
underlying lesion.42
Finally, a variety of endoscopic suturing devices 
have been developed primarily for gastroplication in 
patients with gastro-oesophageal reflux. Endoscopic 
suturing  for  UGIB  management  is  an  attractive 
prospect, but further development of new devices 
is required before endoscopic suturing for UGIB 
can be widely adopted.
“SECOND-LOOK” ENDOSCOPY AND 
ENDOSCOPIC RE-TREATMENT
Routine “second look” endoscopy, in the absence 
of established rebleeding or patient instability, has 
gone out of vogue after studies showed no benefit 
with regards to clinically significant outcomes for 
unselected  patient  populations,65  although  there 
may  be  a  role  in  high  risk  patients.66, 67  Repeat 
therapeutic endoscopy may be indicated (depending 
on local endoscopic and surgical expertise) if there 
is clinical evidence of re-bleeding or if the initial 
therapeutic procedure was unsuccessful or partially 
successful.10, 68  In  expert  hands,  endoscopic  re-
treatment is associated with fewer complications 
and  no  increased  mortality  risk  compared  to 
surgery.69
ACID SUPPRESSION
In vitro studies of the effect of gastric pH on platelet 
aggregation and coagulation provide the rationale 
for  acid  suppression  in  UGIB.  If  gastric  pH  is 
maintained above pH6 (by infusional PPI), platelet 
aggregation is optimized and fibrinolysis relatively 
inhibited,  thereby  potentially  improving  the 
likelihood of clot stability at an ulcer site. Individual 
trials  of  H2  receptor  antagonists  (H2RA)  have 
generally failed to demonstrate a clinical benefit in 
UGIB,70 although one meta-analysis has suggested 
a  weak  effect.71  A  recent  consensus  statement 
suggested that the available data on H2RAs does 
not support their use in ulcer bleeding.10
Several studies have evaluated intravenous proton 
pump  inhibitors  (PPI)  for  non-variceal  UGIB; 
unfortunately,  these  trials  are  heterogeneous  in 
terms of patient population, regimen of PPI and 
timing/type  of  endoscopic  intervention,  making 
comparisons difficult. However, meta-analyses of 
PPIs in non-variceal UGIB have now shown a benefit 
in terms of re-bleeding and need for surgery, but not 
for mortality.2, 72-75 The usual intravenous regime for 
omeprazole therapy in the more robust studies was 
an 80mg intravenous bolus of omeprazole followed 
by a continuous infusion of 8mg/hour for up to 
72 hours. This regimen resulted in a reduction of 
rebleeding from 22.5% to 6.7%, representing a NNT 
of 6 to prevent one person bleeding within 30 days.74 
Subsequent studies using lower intravenous doses 
of omeprazole  76 or high dose oral omeprazole  77-79 
also demonstrated a reduction in rebleeding rate. 
Further study is required to determine the optimum 
dose, route of administration and dosing schedule 
of PPI in UGIB. In the meantime, and with the 
evidence currently available, it seems appropriate 
to treat patients with high risk peptic ulcers with 
intravenous or high dose oral PPI after endoscopic 
therapy has been administered.
FUTURE DIRECTIONS IN ENDOSCOPY
Endoscopic suturing has already been mentioned 
earlier in this article. Currently available suturing 
devices are somewhat awkward to use and are not 
suitable  for  management  of  bleeding,  although 
the principle of suturing peptic ulcers to control 
bleeding  is  well  established  in  surgery.  Further 
development is required before suturing becomes 
possible in the endoscopic sphere.
The risks associated with application of heat to 
bleeding  lesions  are  due  to  the  requirement  for 
tissue contact, lack of control of depth of injury 
and difficulty in treating multiple or diffuse lesions. 
Gastric  freezing  to  achieve  haemostasis  during 
variceal and non-variceal bleeding has been possible 
for several decades although evidence of therapeutic ©  The Ulster Medical Society, 2006.
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benefit from the original techniques was lacking and 
delivery systems were clumsy.80 However, recent 
delivery of new liquid nitrogen or nitrous oxide 
delivery systems has made endoscopic cryotherapy 
feasible although still experimental.81-83 Cryotherapy 
using nitrous oxide relies on the Joule-Thompson 
effect: rapid expansion of compressed gas results in 
a drop in temperature of the gas. The resultant “no 
contact” therapy has been tested in proctitis and may 
also be possible in upper gastrointestinal lesions.
CONCLUSIONS
Non-variceal UGIB remains a significant cause of 
morbidity and mortality. Patients at high risk can be 
identified by risk assessment scoring systems that 
include clinical and endoscopic variables. Adequate 
resuscitation, aggressive endoscopic therapy and 
PPI therapy are effective for achieving haemostasis 
and preventing adverse clinical outcomes, although 
the effect on mortality is low. Multidisciplinary 
care, including endoscopists, surgeons, intensivists 
and radiologists early in the assessment and decision 
stages, is vital to optimise care.
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